Cellular reprogramming to reverse aging and promote organ and tissue regeneration

Patent metadata

Field	Value
Publication number	US-12409207-B2
Application number	US-202318318566-A
Country	US
Kind code	B2
Filing date	May 16, 2023
Priority date	Sep 28, 2018
Publication date	Sep 9, 2025
Grant date	Sep 9, 2025

Abstract

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

First claim

What is claimed is:

1. A syringe comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises an expression vector comprising a polynucleotide encoding a human octamer-binding transcription factor 4 (OCT4) protein, a human sex determining region Y-box 2 (SOX2) protein, and a human Kruppel-like factor 4 (KLF4) protein, wherein the polynucleotide does not encode a Myc proto-oncogene (c-Myc) protein, wherein the polynucleotide does not encode a Nanog protein, wherein the polynucleotide is operably linked to at least one promoter, and wherein the pharmaceutical composition does not comprise a cytokine.

2. The syringe of claim 1 , wherein:
i) the OCT4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 41;
ii) the SOX2 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 43; and
iii) the KLF 4 comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 45.

3. The syringe of claim 1 , wherein:
i) the OCT4 comprises the amino acid sequence of SEQ ID NO: 41;
ii) the SOX2 comprises the amino acid sequence of SEQ ID NO: 43; and
iii) the KLF4 comprises the amino acid sequence of SEQ ID NO: 45.

4. The syringe of claim 1 , wherein the polynucleotide does not encode a homolog of c-Myc and does not encode a homolog of Nanog.

5. The syringe of claim 1 , wherein the polynucleotide is comprised by an adeno-associated virus (AAV).

6. The syringe of claim 1 , wherein the expression vector is an adeno-associated virus (AAV) vector.

7. The syringe of claim 1 , wherein the expression vector is a lentiviral vector.

8. The syringe of claim 1 , wherein the at least one promoter comprises an inducible promoter.

9. The syringe of claim 8 , wherein the inducible promoter comprises:
a mifepristone-responsive promoter, or
a coumermycin-responsive promoter.

10. The syringe of claim 8 , wherein the inducible promoter comprises a tetracycline-responsive element (TRE).

11. The syringe of claim 10 , wherein the syringe comprises a polynucleotide encoding a reverse tetracycline-controlled transactivator (rtTA).

12. The syringe of claim 11 , wherein the expression vector comprises the polynucleotide encoding the rtTA.

13. The syringe of claim 8 , wherein the inducible promoter is a TRE3G promoter.

14. The syringe of claim 1 , wherein the polynucleotide comprises a polynucleotide sequence encoding a self-cleaving peptide.

15. The syringe of claim 8 , wherein the syringe comprises an inducing agent to induce expression of OCT4, SOX2, and/or KLF4.

16. The syringe of claim 15 , wherein the inducing agent is a tetracycline-class antibiotic.

17. The syringe of claim 15 , wherein the inducing agent is tetracycline.

18. The syringe of claim 15 , wherein the inducing agent is doxycycline.

19. The syringe of claim 15 , wherein:
i) OCT4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 41;
ii) SOX2 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 43; and
iii) KLF4 comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 45.

20. The syringe of claim 1 , wherein the expression vector does not encode other transcription factors besides OCT4, SOX2, and KLF4.

Assignees

• Harvard College

Inventors

• Sinclair David A
• Lu Yuancheng

Classifications

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/86

  Viral vectors · CPC title

• A61K31/65

  Tetracyclines · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C07K14/47

  from mammals · CPC title